VivaLNK has announced the results of a survey of pharma, biotech, and clinical research professionals on their opinions about the current state of remote patient monitoring (RPM). Findings unveil significant growth and advancement of RPM technologies throughout the course of the COVID-19 pandemic.
The survey reveals that nearly half (44%) have already adopted RPM for decentralized clinical trials or have plans to within the next 12 months. The adoption of remote monitoring during trials stems largely from COVID-19, as 65% of respondents noted concerns related to the pandemic as their primary driver for using RPM technology.
For more of the survey’s findings, click here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.